Australian pharmacy innovation has been highlighted in a global report launched today by FIP
It’s a “powerful endorsement” of the Society of Hospital Pharmacists of Australia’s role in driving pharmacy workforce change, says SHPA chief executive Kristin Michaels.
Research, development and evaluation strategies for pharmaceutical education and the workforce: a global report follows last year’s Nanjing, China meeting in which pharmacy leaders from around the world met to create a vision for the future.
As well as major reports and 67 statements on the future of pharmacy, 13 Pharmaceutical Workforce Development Goals were released.
These are the primary measurement of 21 countries’ capacity and ability to implement FIP’s vision of a global pharmacy workforce ready to meet the health care challenges of the future.
FIP’s new report, launched at the Seoul conference which is currently underway, is aimed at providing guidance on aligning national research, development and evaluation projects with the global vision and these workforce goals.
Australian pharmacy initiatives were recognised across 10 of 13 Pharmaceutical Workforce Development Goals.
This international analysis of national-level research, development and evaluation strategies for pharmaceutical workforces is significant, as it is the first report produced since the Nanjing roadmap,” says SHPA’s Ms Michaels.
Five Australia-first SHPA initiatives were highlighted in the global report of international standard-setting including:
- SHPA Residency Program – PWDG 2: Foundation training and early career development)
- Partnership agreement with the Royal Pharmaceutical Society, GB – PWDG 4: Advanced and specialist expert development
- SHPA ClinCAT (Clinical Competency Assessment Tool) – PWDG 5: Competency development
- The National Translational Research Collaborative (NTRC) – PWDG 8: Working with others in the healthcare team.
- The Pharmacy Technician and Assistant Role Redesign Project – PWDG 13: Workforce policy formation.
Also highlighted were collaborative efforts toward establishing a sustainable Advanced Practice framework in Australia, and advocating for government investment in modelling and pharmacist workforce planning.
Ms Michaels says the report highlights the need for greater understanding of how to evaluate the impact of pharmacy workforces.
“It was positive to see the FIP acknowledge this impact is largely missing from research literature,” she says.
“On behalf of our members, who are committed to evidence-based practice, SHPA plans to respond to this gap through accumulation of workforce development and impact research through the Pharmacy Impact Initiative, currently in development.”
Professor Ian Bates, Director of FIP Education commended Australia’s performance.
“This is a remarkable achievement and I applaud SHPA for its efforts for taking a lead in the continued development of these Pharmaceutical Workforce Development Goals,” he says.
“The clear alignment with the FIP roadmap and WHO health workforce imperatives is welcome and demonstrates strong leadership for this critical health workforce, ensuring Australia has the capability and adaptability to remain responsive to complex medicines management demands and evolving technology.”